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Hepatitis E virus (HEV) infection is a common cause of
acute hepatitis in several parts of the world, particularly
developing countries where there is poor sanitation and
environmental conditions.1,2 In these endemic regions,
HEV infection accounts for a considerable proportion
of acute sporadic hepatitis. During hepatitis E out-
breaks, the predominant route of transmission of HEV
has been fecal-oral, in particular through consumption
of contaminated drinking water.3–5
Infections that are transmitted by the fecal-oral route,
namely hepatitis A, polio virus and rotavirus infection,
frequently have a high rate of person-to-person trans-
mission. However, surprisingly, person-to-person trans-
mission of HEV infection is distinctly uncommon.
During outbreaks of hepatitis E, secondary attack rates
among household contacts of cases is only 0.7 to
2.2%.1,2 Even when multiple cases occur in a family,
these are usually related to a common water source.6 We
have recently shown person-to-person transmission to
be uncommon in sporadic hepatitis E also.7
Vertical transmission of HEV infection from mother
to infant is known. In one study, five of eight babies
born to mothers with acute hepatitis E had HEV RNA
in their blood specimens obtained at birth.8
Several hepatotropic viruses, namely hepatitis B virus
(HBV), hepatitis C virus (HCV) and hepatitis D virus
(HDV) are transmitted primarily through the parenteral
route. In contrast, hepatitis A and E are transmitted pri-
marily by the fecal-oral route. Hepatitis A can rarely be
transmitted through blood transfusion.9 Generally,
HEV is believed not to be transmitted through blood
transfusions because viremia during infection with this
virus lasts for only a short period.10 Also, anti-HEV anti-
body prevalence rates among patients with hemo-
philia,11 thalassemia, patients on hemodialysis and
intravenous drug users are no higher than those in the
general population.12
In this issue of the Journal, Khuroo et al.13 provide
data to indicate that HEV infection can be transmitted
through blood transfusion. Their study had several
components. First, they showed that serological evi-
dence of HEV infection was more frequent among those
who had received blood transfusions than among non-
transfused controls. Second, they found that a small
proportion of healthy blood donors had evidence of
subclinical HEV infection and viremia. Third, individ-
uals who had received blood from these donors with
subclinical HEV infection developed evidence of HEV
infection after transfusion. These data suggest (i) fre-
quent existence of subclinical infection and viremia due
to HEV among healthy persons residing in HEV-
endemic regions, and (ii) the possibility of transmission
of this virus through blood transfusions. These data
raise several questions. Let us look at these one by one.
Are these data entirely novel? Individual pieces of
information included in the paper by Khuroo et al.13
have been reported previously. Mathur et al.,14 using an
in-house assay, found IgM anti-HEV antibodies in 244
of 2070 (11.8%) children residing in northern India
and attending medical facilities for minor ailments, sug-
gesting that subclinical HEV infection was frequent.
However, they did not test these sera for HEV RNA.
Arankalle et al.15 found HEV RNA in sera from three of
200 blood donors in India; of these three donors, only
one had detectable IgM anti-HEV antibodies. However,
they did not follow-up the recipients of HEV RNA-
positive blood. In another study,16 Arankalle et al. tested
serial sera from 37 IgG anti-HEV-negative transfusion
recipients and found evidence of seroconversion to IgM
and IgG anti-HEV in two patients; in contrast, none of
the 34 non-transfused controls showed such serocon-
version. However, the implicated donor blood units
tested negative for HEV RNA, casting a shadow on
blood transfusion as the route of transmission. Alterna-
tively, this finding may reflect poor sensitivity of tests for
HEV RNA. The current study by Khuroo et al.,13 in
contrast, provides data concurrently on all pieces of the
puzzle. It thus represents a significant advance on the
previously available data.
Do these data conclusively prove transmission of
HEV through blood transfusion? Ideally, one would
have liked the authors to show identity or close homol-
ogy of genomic sequences of HEV isolates from the
infected donor blood and from clinical specimens
obtained from recipients with post-transfusion hepatitis
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E. Such studies have recently been used to prove trans-
mission of HEV through consumption of undercooked
meat infected with HEV.17 However, even in the
absence of such data, the evidence provided by the
authors is fairly convincing.
Do the data reported by Khuroo et al.13 have some
inconsistency? In the prospective part of their study,
nearly 4% of healthy blood donors (four of 107, includ-
ing three with IgM anti-HEV) had HEV RNA
(Table 1). In contrast, in the initial retrospective study,
only two of 250 (0.8%) healthy controls and none of
115 healthy subjects with remote history of transfusion
had detectable IgM anti-HEV and/or HEV RNA
(Table 1). This significant difference (4/107 vs 2/365;
P < 0.05, Fisher’s exact test; EpiInfo, version 6) in fre-
quency of subclinical HEV infection rates in the two
phases of their study is somewhat puzzling. Even more
disconcerting are a still wider range of IgM anti-HEV
seroprevalence rates reported among healthy subjects in
other studies from India, varying from as low as none of
412 blood donors16 to 11.4% of healthy children.14
These variations call for studies of a larger number of
healthy subjects in HEV-endemic populations.
What is the clinical relevance of transmission of HEV
infection through blood transfusions? Khuroo et al.13
found HEV infection in three of their 22 susceptible
transfusion recipients; of these three, one each had mild
clinical hepatitis, subclinical alanine aminotransferase
(ALT) elevation and no evidence of liver injury. In the
study by Arankalle et al.,16 of the two transfusion recip-
ients who developed HEV infection, neither developed
symptoms and one had ALT elevation. Thus, based on
these limited data on five patients, post-transfusion hep-
atitis E was usually not a clinical problem. Further-
more, given the high rates of fecal-oral transmission of
hepatitis E in disease-endemic regions, the parenterally
acquired hepatitis E is likely to constitute only a minute
proportion of all hepatitis E cases.
Do these data indicate the need to introduce screen-
ing measures to prevent transmission of HEV through
blood transfusion? Currently, the answer will be ‘no’. To
introduce such measures, we need to be certain that
post-transfusion hepatitis E poses a significant disease
burden and that we have a method that reliably prevents
such transmission. Various candidate screening tests for
this purpose may include ALT levels, IgM anti-HEV
and HEV RNA. ALT testing, although simple to per-
form, is unlikely to be effective. In the studies by
Khuroo et al.13 and Arankalle et al.,16 ALT elevation was
observed in only two of four and one of three donor
blood units that contained HEV RNA, respectively. In
another study, only 7% of IgM anti-HEV positive sera
from healthy children had ALT levels exceeding twice
the upper limit of normal.14 Thus, ALT elevation is pos-
sibly too insensitive for this purpose. Furthermore, in a
study from India,18 16.5% of blood units had ALT ele-
vation, indicating that this test would lead to an unac-
ceptably high rate of wastage of donated blood. HEV
RNA testing is impractical in resource-poor HEV-
endemic regions. Further studies are needed on the
specificity of IgM anti-HEV assays in blood bank sera
with a low prevalence of HEV infection.
Do the new observations alter our current under-
standing of hepatitis E? Possibly, yes. If confirmed by
other groups, these findings may have a major impact
on our understanding of HEV epidemiology. In an
experimental animal model, subclinical HEV infection
has been shown to be associated with excretion in feces
of large quantities of viable virus, which is capable of
transmitting infection to naïve animals.19 This led to the
hypothesis that repeated subclinical passage of HEV in
humans and consequent shedding of large quantities of
viable virus may represent a potential reservoir of HEV,
somewhat akin to the situation with polio virus. The
demonstration by Khuroo et al.13 of subclinical HEV
infection provides support for this hypothesis.
Khuroo et al.13 found the IgG anti-HEV positivity
rates to be relatively lower than would be expected from
contemporaneous IgM positivity rates in various study
groups (Table 1). After acute HEV infection, IgM anti-
bodies persist for approximately 5 months. Although
the exact duration of persistence of IgG antibodies is
not known, these are believed to persist for several
years.1,2,20 Thus, one would expect the prevalence of IgG
to be several fold higher than that of IgM. The relatively
low ratio of IgG:IgM positivity rates observed by
Khuroo et al. would suggest that IgG antibodies
become undetectable fairly rapidly. Furthermore, fre-
quent occurrence of HEV infections, both clinical and
subclinical, among adults in HEV-endemic regions
despite a high rate of subclinical HEV infection suggests
absence of significant protection against reinfection. If
this is true, attempts at eradicating hepatitis E through
the development of an immunogenic vaccine may prove
to be unsuccessful. In fact, in animal studies, the pro-
tective effect of a putative HEV vaccine has been found
to be short-lasting.21
Another issue that will need to be answered is the
possible mode(s) of acquisition of frequent subclinical
HEV infection. This is particularly important because
person-to-person spread has been shown to be infre-
quent in both epidemic and sporadic hepatitis E.6,7
Table 1 Frequency of various hepatitis E virus (HEV) markers in the study by Khuroo et al.13
Group n IgM anti-HEV or HEV RNA (%) IgG anti-HEV (%)
Healthy controls in the retrospective study 250 2 (0.8) 10 (4.0)
Subjects with history of remote transfusion
in retrospective study
115 0 (0) 9 (7.8)
Blood donors in the prospective study 107 4 (3.7) 11 (10.3)
Total 472 6 (1.3) 30 (6.4)
Hepatitis E and parenteral transmission 731
In conclusion, Khuroo et al’s data on transmission of
hepatitis E through blood transfusions represent an
advance in our knowledge about the disease. However,
larger studies are needed to determine the frequency of
such transmission in disease-endemic regions. If such
transmission is indeed found to be common, we will
need to find out methods to prevent it. In addition,
there is an urgent need to study in more detail the fre-
quency and consequences of subclinical HEV infection,
if we wish to fully understand the epidemiology of this
‘E’nigmatic virus.
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